Ion Exchange executes Technology Transfer Agreement with MANN + HUMMEL for PVDF membranes

1 min read     Updated on 30 Apr 2026, 08:41 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Ion Exchange (India) Limited has executed a Technology Transfer Agreement with MANN + HUMMEL for the manufacture of PVDF Ultrafiltration membranes and Integrated Membrane Bioreactor systems. The collaboration involves a 7.50% technology transfer fee on revenue generated from manufactured products and will strengthen Ion Exchange's HYDRAMEM® solutions portfolio while enabling locally manufactured, globally benchmarked membrane technology.

powered bylight_fuzz_icon
39016440

*this image is generated using AI for illustrative purposes only.

Ion Exchange (India) Limited has executed a Technology Transfer Agreement with MANN + HUMMEL for the manufacture of PVDF Ultrafiltration (UF) membranes and Integrated Membrane Bioreactor (MBR) systems. The agreement was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on April 29, 2026.

Agreement Details

The collaboration encompasses both domestic and international operations. Under the agreement, MANN + HUMMEL will transfer technology for the production of advanced PVDF hollow fiber ultrafiltration membranes with integrated UltraSKID systems, followed by technology transfer for Membrane Bioreactor solutions for deployment in India.

Parameter: Details
Technology Transfer Fee: 7.50% on revenue generated from manufactured products
Related Party Transaction: Not a related party transaction
Scope: Manufacturing, system integration, and commercialization of PVDF UF membranes
Production Location: Ion Exchange's expanded HYDRAMEM® facility in Goa

Production and Strategic Benefits

Production will be conducted at Ion Exchange's expanded HYDRAMEM® membrane manufacturing facility in Goa. The agreement includes the transfer of technical know-how, covering manufacturing processes, formulations, and best practices. Ion Exchange will manufacture, undertake system integration, and commercialize PVDF hollow fiber ultrafiltration membranes along with integrated UltraSKID systems based on MANN+HUMMEL's advanced technology.

Expected Benefits and Rationale

The collaboration strengthens Ion Exchange's HYDRAMEM® solutions to offer an integrated portfolio of membrane-based technologies, including Ultrafiltration (UF), Reverse Osmosis (RO) and Membrane Bioreactor (MBR) systems. The strategic partnership aims to enable the delivery of globally benchmarked membrane technology manufactured locally, reduce import dependence, and ensure improved supply reliability with faster delivery timelines for customers.

Regulatory Compliance Details

The agreement has been entered into in the ordinary course of business and is expected to support the Company's long-term strategic and technological objectives. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, providing comprehensive details of the strategic technology transfer and manufacturing collaboration.

Historical Stock Returns for Ion Exchange

1 Day5 Days1 Month6 Months1 Year5 Years
-0.23%-3.26%+18.95%-0.40%-23.43%+112.02%

How will this technology transfer impact Ion Exchange's competitive positioning against international membrane manufacturers in the Indian market?

What is the expected timeline for Ion Exchange to achieve full production capacity and begin generating significant revenue from the PVDF membrane manufacturing?

Could this partnership lead to Ion Exchange becoming a regional manufacturing hub for MANN + HUMMEL's membrane technologies in South Asia?

Ion Exchange (India) Limited Announces Postal Ballot for Employee Stock Option Scheme 2026

3 min read     Updated on 25 Apr 2026, 07:18 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Ion Exchange (India) Limited has issued a postal ballot notice dated March 18, 2026, seeking member approval for the Ion Exchange (India) Limited – Employee Stock Option Scheme 2026. The scheme proposes granting up to 17,00,000 employee stock options to eligible employees of the company and its subsidiaries, with shares to be acquired through secondary acquisition via the Ion Exchange ESOP Trust. Remote e-voting will be available from April 25, 2026, to May 24, 2026, with results expected by May 26, 2026. The company also seeks approval for providing financial assistance to the trust, limited to 5% of paid-up capital and free reserves.

powered bylight_fuzz_icon
38627334

*this image is generated using AI for illustrative purposes only.

Ion Exchange (India) Limited has issued a postal ballot notice dated March 18, 2026, seeking member approval for the Ion Exchange (India) Limited – Employee Stock Option Scheme 2026. The notice, submitted to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines four special resolutions requiring shareholder consent.

Proposed Resolutions

The postal ballot seeks approval for four key matters related to the ESOP 2026:

Item No. Description Type of Resolution
1 To consider and approve 'Ion Exchange (India) Limited – Employee Stock Option Scheme 2026' Special Resolution
2 To consider and approve grant of employee stock options to employees of subsidiary company(ies) under the scheme Special Resolution
3 To consider and approve secondary acquisition of shares through Trust route for implementation of the scheme Special Resolution
4 To consider and approve provision of money by the Company for purchase of its own Shares by the Trust Special Resolution

Key Scheme Details

The ESOP 2026 proposes to grant up to 17,00,000 employee stock options, each convertible into one equity share of face value of Re. 1/- each. The scheme will be implemented through an irrevocable employee welfare trust named 'Ion Exchange ESOP Trust'. The shares required for the scheme will be sourced from secondary acquisition, representing approximately 1.16% of the paid-up capital.

The vesting period for options ranges from a minimum of 1 year to a maximum of 4 years from the date of grant. The exercise price will be determined by the Committee, subject to a maximum discount of up to 15% on the market price, but not less than the face value. The exercise period for vested options is a maximum of 4 years from the date of vesting.

Financial Assistance and Eligibility

The company seeks approval to provide financial assistance to the trust, limited to 5% of the aggregate of paid-up capital and free reserves. The loan may be interest-bearing or interest-free, with tenure based on the scheme term, and will be repayable from proceeds of exercise, permitted sale, or transfer of shares.

Eligible participants include employees working in India or outside India, directors (excluding independent directors), and employees of subsidiary companies. Promoters and persons belonging to the promoter group are excluded from eligibility. The maximum options per employee per grant shall not exceed 100,000, with an aggregate limit of 4,00,000 options per employee.

E-Voting Schedule

The remote e-voting facility will be available through NSDL during the following period:

Event Date and Time
Commencement of e-voting 9.00 a.m. (IST) on Saturday, April 25, 2026
End of e-voting 5.00 p.m. (IST) on Sunday, May 24, 2026
Results declaration On or before Tuesday, May 26, 2026

The postal ballot notice is being sent electronically to members whose email addresses are registered with the company, its Registrar and Transfer Agent, or Depository Participants as on the cut-off date of Friday, April 17, 2026. The notice and e-voting instructions are available on the company's website and NSDL's e-voting portal.

Historical Stock Returns for Ion Exchange

1 Day5 Days1 Month6 Months1 Year5 Years
-0.23%-3.26%+18.95%-0.40%-23.43%+112.02%

How might the 17 lakh stock options impact Ion Exchange's talent retention and recruitment capabilities in India's competitive engineering services market?

What could be the potential financial implications if the company needs to utilize the full 5% of paid-up capital and free reserves for the ESOP Trust funding?

Will this ESOP scheme influence Ion Exchange's expansion strategy into international markets, given its inclusion of employees working outside India?

More News on Ion Exchange

1 Year Returns:-23.43%